International Journal of Medicinal Chemistry

Copyright © 2017 Neelaveni Thangavel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. G. Danaei, M. M. Finucane, Y. Lu et al., “National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants,” The Lancet, vol. 378, no. 9785, pp. 31–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
2. “Global report on Diabetes. World Health Organization,” Geneva, 2016, http://www.who.int/mediacentre/factsheets/.
3. D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers, “Metformin: an update,” Annals of Internal Medicine, vol. 137, no. 1, pp. 25–33, 2002. View at Publisher · View at Google Scholar · View at Scopus
4. S. E. Inzucchi, “Oral antihyperglycemic therapy for type 2 diabetes: scientific review,” Journal of American Medical Association, vol. 287, pp. 360–372, 2002. View at Google Scholar
5. M. Diamant and R. J. Heine, “Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence,” Drugs, vol. 63, no. 13, pp. 1373–1405, 2003. View at Publisher · View at Google Scholar · View at Scopus
6. T. M. O’Moore-Sullivam and J. B. Prins, “Thiazolidinediones and type 2 diabetes: new drug for old disease,” Medical Journal of Australia, vol. 176, pp. 381–386, 2002. View at Google Scholar
7. F. Lalloyer and B. Staels, “Fibrates, glitazones, and peroxisome proliferator-activated receptors,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 5, pp. 894–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
8. J. Al-Salman, H. Arjomand, D. G. Kemp, and M. Mittal, “Hepatocellular injury in a patient receiving rosiglitazone: A case report,” Annals of Internal Medicine, vol. 132, no. 2, pp. 121–124, 2000. View at Publisher · View at Google Scholar · View at Scopus
9. L. M. Forman, D. A. Simmons, and R. H. Diamond, “Hepatic failure in a patient taking rosiglitazone,” Annals of Internal Medicine, vol. 132, no. 2, pp. 118–121, 2000. View at Publisher · View at Google Scholar · View at Scopus
10. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar · View at Scopus
11. J. D. Brown and J. Plutzky, “Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets,” Circulation, vol. 115, no. 4, pp. 518–533, 2007. View at Publisher · View at Google Scholar · View at Scopus
12. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at Scopus
13. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar · View at Scopus
14. J. Berger and J. A. Wagner, “Physiological and therapeutic roles of peroxisome proliferator-activated receptors,” Diabetes Technology and Therapeuticies, vol. 4, pp. 163–174, 2002. View at Google Scholar
15. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
16. V. Zoete, A. Grosdidier, and O. Michielin, “Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 915–925, 2007. View at Publisher · View at Google Scholar · View at Scopus
17. A. I. Shulman and D. J. Mangelsdorf, “Retinoid X receptor heterodimers in the metabolic syndrome,” New England Journal of Medicine, vol. 353, no. 6, pp. 604–615, 2005. View at Publisher · View at Google Scholar · View at Scopus
18. S. Heikkinen, J. Auwerx, and C. A. Argmann, “PPARγ in human and mouse physiology,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 999–1013, 2007. View at Publisher · View at Google Scholar · View at Scopus
19. N. Viswakarma, Y. Jia, L. Bai et al., “Coactivators in PPAR-regulated gene expression,” PPAR Research, vol. 2010, Article ID 250126, 21 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
20. S. Yu and J. K. Reddy, “Transcription coactivators for peroxisome proliferator-activated receptors,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 936–951, 2007. View at Publisher · View at Google Scholar · View at Scopus
21. J. N. Feige and J. Auwerx, “Transcriptional coregulators in the control of energy homeostasis,” Trends in Cell Biology, vol. 17, no. 6, pp. 292–301, 2007. View at Publisher · View at Google Scholar · View at Scopus
22. V. Chandra, P. Huang, Y. Hamuro et al., “Structure of the intact PPAR-γ-RXR-α nuclear receptor complex on DNA,” Nature, vol. 456, no. 7220, pp. 350–356, 2008. View at Publisher · View at Google Scholar · View at Scopus
23. D. L. Bain, A. F. Heneghan, K. D. Connaghan-Jones, and M. T. Miura, “Nuclear receptor structure: Implications for function,” Annual Review of Physiology, vol. 69, pp. 201–220, 2007. View at Publisher · View at Google Scholar · View at Scopus
24. S. Khorasanizadeh and F. Rastinejad, “Nuclear-receptor interactions on DNA-response elements,” Trends in Biochemical Sciences, vol. 26, no. 6, pp. 384–390, 2001. View at Publisher · View at Google Scholar · View at Scopus
25. Q. Zhao, S. Khorasanizadeh, Y. Miyoshi, M. A. Lazar, and F. Rastinejad, “Structural elements of an orphan nuclear receptor-DNA complex,” Molecular Cell, vol. 1, no. 6, pp. 849–861, 1998. View at Publisher · View at Google Scholar · View at Scopus
26. L. Nagy and J. W. R. Schwabe, “Mechanism of the nuclear receptor molecular switch,” Trends in Biochemical Sciences, vol. 29, no. 6, pp. 317–324, 2004. View at Publisher · View at Google Scholar · View at Scopus
27. R. T. Gampe Jr., V. G. Montana, M. H. Lambert et al., “Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors,” Molecular Cell, vol. 5, no. 3, pp. 545–555, 2000. View at Publisher · View at Google Scholar · View at Scopus
28. H. E. Xu, M. H. Lambert, V. G. Montana et al., “Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13919–13924, 2001. View at Publisher · View at Google Scholar · View at Scopus
29. S. Ebdrup, I. Pettersson, H. B. Rasmussen et al., “Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor α/γ agonist ragaglitazar,” Journal of Medicinal Chemistry, vol. 46, no. 8, pp. 1306–1317, 2003. View at Publisher · View at Google Scholar · View at Scopus
30. S.-H. Sheu, T. Kaya, D. J. Waxman, and S. Vajda, “Exploring the binding site structure of the PPARγ ligand-binding domain by computational solvent mapping,” Biochemistry, vol. 44, no. 4, pp. 1193–1209, 2005. View at Publisher · View at Google Scholar · View at Scopus
31. S. Neschen, K. Morino, J. Dong et al., “n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner,” Diabetes, vol. 56, no. 4, pp. 1034–1041, 2007. View at Publisher · View at Google Scholar · View at Scopus
32. J. C. Fruchart, B. Staels, and P. Duriez, “The role of fibric acids in atherosclerosis,” Current Atherosclerosis Report, vol. 3, no. 1, pp. 83–92, 2001. View at Google Scholar
33. S. Sethi, O. Ziouzenkova, H. Ni, D. D. Wagner, J. Plutzky, and T. N. Mayadas, “Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARα,” Blood, vol. 100, no. 4, pp. 1340–1346, 2002. View at Publisher · View at Google Scholar · View at Scopus
34. M. Rakhshandehroo, B. Knoch, M. Müller, and S. Kersten, “Peroxisome proliferator-activated receptor alpha target genes,” PPAR Research, vol. 2010, Article ID 612089, 20 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
35. J. B. Schwimmer, C. Behling, R. Newbury et al., “Histopathology of pediatric nonalcoholic fatty liver disease,” Hepatology, vol. 42, no. 3, pp. 641–649, 2005. View at Publisher · View at Google Scholar · View at Scopus
36. B. Grygiel-Górniak, “Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications—a review,” Nutrition Journal, vol. 13, article 17, 2014. View at Publisher · View at Google Scholar · View at Scopus
37. A. Taniguchi, M. Fukushima, M. Sakai et al., “Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients,” Metabolism, vol. 50, no. 4, pp. 477–480, 2001. View at Publisher · View at Google Scholar · View at Scopus
38. G. Chinetti-Gbaguidi, J.-C. Fruchart, and B. Staels, “Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy,” Current Opinion in Pharmacology, vol. 5, no. 2, pp. 177–183, 2005. View at Publisher · View at Google Scholar · View at Scopus
39. A. Keech, R. J. Simes, and P. Barter, “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FLEID study): randomized controlled trial,” Lancet, vol. 366, pp. 1849–1861, 2005. View at Google Scholar
40. G. Wölkart, A. Schrammel, K. Dörffel, G. Haemmerle, R. Zechner, and B. M. Mayer, “Cardiac dysfunction in adipose triglyceride lipase deficiency: Treatment with a PPARα agonist,” British Journal of Pharmacology, vol. 165, no. 2, pp. 380–389, 2012. View at Publisher · View at Google Scholar · View at Scopus
41. M. Tsunoda, N. Kobayashi, T. Ide, M. Utsumi, M. Nagasawa, and K. Murakami, “A novel PPARα agonist ameliorates insulin resistance in dogs fed a high-fat diet,” American Journal of Physiology - Endocrinology and Metabolism, vol. 294, no. 5, pp. E833–E840, 2008. View at Publisher · View at Google Scholar · View at Scopus
42. H. L. Schäfer, W. Linz, E. Falk et al., “AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats,” Acta Pharmacologica Sinica, vol. 33, no. 1, pp. 82–90, 2012. View at Publisher · View at Google Scholar · View at Scopus
43. D. Capelli, C. Cerchia, and R. Montanari, “Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode,” Scientific Reports, vol. 6, Article ID 34792. View at Publisher · View at Google Scholar
44. Y. Zhu, C. Qi, J. R. Korenberg et al., “Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 17, pp. 7921–7925, 1995. View at Publisher · View at Google Scholar · View at Scopus
45. G. Medina-Gomez, S. L. Gray, L. Yetukuri et al., “PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism,” PLoS Genetics, vol. 3, no. 4, p. e64, 2007. View at Publisher · View at Google Scholar · View at Scopus
46. I. B. Sears, M. A. MacGinnitie, L. G. Kovacs, and R. A. Graves, “Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma,” Molecular and Cellular Biology, vol. 16, no. 7, pp. 3410–3419, 1996. View at Publisher · View at Google Scholar · View at Scopus
47. C. Christodoulides and A. Vidal-Puig, “PPARs and adipocyte function,” Molecular and Cellular Endocrinology, vol. 318, no. 1-2, pp. 61–68, 2010. View at Publisher · View at Google Scholar · View at Scopus
48. U. Kintscher and R. E. Law, “PPARγ-mediated insulin sensitization: the importance of fat versus muscle,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 288, no. 2, pp. E287–E291, 2005. View at Publisher · View at Google Scholar · View at Scopus
49. M. Ahmadian, J. M. Suh, N. Hah et al., “PPARγ signaling and metabolism: the good, the bad and the future,” Nature Medicine, vol. 19, no. 5, pp. 557–566, 2013. View at Publisher · View at Google Scholar
50. W. Huang and C. K. Glass, “Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 8, pp. 1542–1549, 2010. View at Publisher · View at Google Scholar · View at Scopus
51. C. K. Glass and K. Saijo, “Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells,” Nature Reviews Immunology, vol. 10, no. 5, pp. 365–376, 2010. View at Publisher · View at Google Scholar · View at Scopus
52. P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
53. S. Han and J. Roman, “Peroxisome proliferator-activated receptor γ: A novel target for cancer therapeutics?” Anti-Cancer Drugs, vol. 18, no. 3, pp. 237–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
54. A. K. Reka, H. Kurapati, V. R. Narala et al., “Peroxisome proliferator-activated receptor-γ activation inhibits tumor metastasis by antagonizing smad3-mediated epithelial-mesenchymal transition,” Molecular Cancer Therapeutics, vol. 9, no. 12, pp. 3221–3232, 2010. View at Publisher · View at Google Scholar · View at Scopus
55. T. Itoh, L. Fairall, K. Amin et al., “Structural basis for the activation of PPARgamma by oxidized fatty acids,” Nature Structural and Molecular Biology, vol. 15, no. 9, pp. 924–931, 2008. View at Publisher · View at Google Scholar · View at Scopus
56. M. H. Tan, “Current treatment of insulin resistance in type 2 diabetes mellitus,” Journal of Clinical Practice Supplement, vol. 113, pp. 54–62, 2000. View at Google Scholar
57. M. A. Deeg and M. H. Tan, “Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins and adiponectin in head-to-head randomized clinical studies,” PPAR Research, vol. 2008, Article ID 520465, 6 pages, 2008. View at Publisher · View at Google Scholar
58. A. Krishnaswami, S. Ravikumar, and J. M. Lewis, “Thiazolidinediones: a 2010 perspective,” The Permanente Journal, vol. 14, no. 3, pp. 64–72, 2010. View at Google Scholar
59. N. Maeda, M. Takahashi, T. Funahashi et al., “PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein,” Diabetes, vol. 50, no. 9, pp. 2094–2099, 2001. View at Publisher · View at Google Scholar · View at Scopus
60. T. Yamauchi, J. Kamon, H. Waki et al., “The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity,” Nature Medicine, vol. 7, no. 8, pp. 941–946, 2001. View at Publisher · View at Google Scholar · View at Scopus
61. B. Staels and J.-C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005. View at Publisher · View at Google Scholar · View at Scopus
62. S. M. Rangwala, B. Rhoades, J. S. Shapiro et al., “Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity,” Developmental Cell, vol. 5, no. 4, pp. 657–663, 2003. View at Publisher · View at Google Scholar · View at Scopus
63. G. Bolli, F. Dotta, E. Rochotte, and S. E. Cohen, “Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study,” Diabetes, Obesity and Metabolism, vol. 10, no. 1, pp. 82–90, 2008. View at Publisher · View at Google Scholar · View at Scopus
64. G. Derosa and P. Maffioli, “Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk,” Current Molecular Pharmacology, vol. 5, no. 2, pp. 272–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
65. T. M. Larsen, S. Toubro, and A. Astrup, “PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?” International Journal of Obesity, vol. 27, no. 2, pp. 147–161, 2003. View at Publisher · View at Google Scholar · View at Scopus
66. A. J. Gilde, J.-C. Fruchart, and B. Staels, “Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease,” Journal of the American College of Cardiology, vol. 48, no. 9, pp. A24–A32, 2006. View at Publisher · View at Google Scholar · View at Scopus
67. M. Lu, D. A. Sarruf, S. Talukdar et al., “Brain PPAR-γ promotes obesity and is required for the insuling-sensitizing effect of thiazolidinediones,” Nature Medicine, vol. 17, no. 5, pp. 618–622, 2011. View at Publisher · View at Google Scholar · View at Scopus
68. D. E. Kemp, M. Schinagle, K. Gao et al., “PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression,” CNS Drugs, vol. 28, no. 6, pp. 571–581, 2014. View at Publisher · View at Google Scholar
69. W. C. Jeffrey, “Current developments in thiazolidinediones,” Advances in Health Science Research, vol. 1, pp. 1–6, 2011. View at Google Scholar
70. E. A. M. Gale, “Lessons from the glitazones: A story of drug development,” Lancet, vol. 357, no. 9271, pp. 1870–1875, 2001. View at Publisher · View at Google Scholar · View at Scopus
71. T. M. Willson, M. H. Lambert, and S. A. Kliewer, “Peroxisome proliferator-activated receptor γ and metabolic disease,” Annual Review of Biochemistry, vol. 70, pp. 341–367, 2001. View at Publisher · View at Google Scholar · View at Scopus
72. A. Farce, N. Renault, and P. Chavatte, “Structural insight into PPARγ ligands binding,” Current Medicinal Chemistry, vol. 16, no. 14, pp. 1768–1789, 2009. View at Publisher · View at Google Scholar · View at Scopus
73. M. V. Liberato, A. S. Nascimento, S. D. Ayers et al., “Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and Pan-PPAR partial agonists,” PLoS ONE, vol. 7, no. 5, Article ID e36297, 2012. View at Publisher · View at Google Scholar · View at Scopus
74. J. K. Alice and B. B. John, “Review of the structural and dynamic mechanisms of PPARγ partial agonism,” PPAR Research, vol. 2015, Article ID 816856, 15 pages, 2015. View at Publisher · View at Google Scholar
75. J. H. Choi, A. S. Banks, J. L. Estall et al., “Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ 3 by Cdk5,” Nature, vol. 466, no. 7305, pp. 451–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
76. S. Kaczanowski and P. Zielenkiewicz, “Why similar protein sequences encode similar three-dimensional structures?” Theoretical Chemistry Accounts, vol. 125, no. 3-6, pp. 643–650, 2010. View at Publisher · View at Google Scholar · View at Scopus
77. W. A. Russu, “Thiazolidinedione anti-cancer activity: Is inhibition of microtubule assembly implicated?” Medical Hypotheses, vol. 68, no. 2, pp. 343–346, 2007. View at Publisher · View at Google Scholar · View at Scopus
78. F. Fajeelath and L. Baskar, “Thiazolidinediones as a privileged structural scaffold in PPAR agonists: a review,” International Journal of Pharmaceutical Chemistry, vol. 6, no. 5, pp. 124–141, 2016. View at Google Scholar
79. C. Prabhakar, G. Madhusudhan, K. Sahadev et al., “Synthesis and biological activity of novel thiazolidinediones,” Bioorganic and Medicinal Chemistry Letters, vol. 8, no. 19, pp. 2725–2730, 1998. View at Publisher · View at Google Scholar · View at Scopus
80. E. Adeghate, A. Adem, M. Y. Hasan, K. Tekes, and H. Kalasz, “Medicinal chemistry and actions of dual and pan PPAR modulators,” Open Medicinal Chemistry Journal, vol. 5, no. 2, pp. 93–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
81. M. Deepanwita and S. Subir, “A review on the role of peroxisome proliferator-activated recptor-γ agonists and hybrids in type 2 diabetes and cardiomyopathy,” Asian Journal of Pharmaceutical Clinical Research, vol. 8, no. 2, pp. 26–31, 2015. View at Google Scholar
82. S. A. Hayat, B. Patel, R. S. Khattar, and R. A. Malik, “Diabetic cardiomyopathy: Mechanisms, diagnosis and treatment,” Clinical Science, vol. 107, no. 6, pp. 539–557, 2004. View at Publisher · View at Google Scholar · View at Scopus
83. G. E. W. Alan, New Horizons in Predictive Toxicology: Current Status and Application, Royal Society of Chemistry, Europe, 2011. View at Publisher · View at Google Scholar
84. M. Imran, B. Ilyas, Deepanjali, and A. K. Suroor, “Recent thiazolidinediones as antidiabetics,” Journal of Scientific and Industrial Research, vol. 66, pp. 99–109, 2007. View at Google Scholar
85. M. Nomura, S. Kinoshita, H. Satoh et al., “(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents,” Bioorganic and Medicinal Chemistry Letters, vol. 9, no. 4, pp. 533–538, 1999. View at Publisher · View at Google Scholar · View at Scopus
86. H. Yanagisawa, T. Fujita, K. Fujimoto et al., “Oxime containing thiazolidinedione derivatives and analogs, their preparation, and their therapeutic use against diabetes and related conditions,” European Patent, 708, 098, August, 1997.
87. C. H. Georbitz and M. C. Etter, “Hydrogen bonds to carboxylate groups. The question of three-center interactions,” Journal of Chemical Society, Perkin Transactions, vol. 2, pp. 131–135, 1992. View at Google Scholar
88. T. S. G. Olsson, M. A. Williams, W. R. Pitt, and J. E. Ladbury, “The Thermodynamics of Protein-Ligand Interaction and Solvation: Insights for Ligand Design,” Journal of Molecular Biology, vol. 384, no. 4, pp. 1002–1017, 2008. View at Publisher · View at Google Scholar · View at Scopus
89. K. A. Dill, T. M. Truskett, V. Vlachy, and B. Hribar-Lee, “Modeling water, the hydrophobic effect, and ion solvation,” Annual Review of Biophysics and Biomolecular Structure, vol. 34, pp. 173–199, 2005. View at Publisher · View at Google Scholar · View at Scopus
90. B. J. Berne, J. D. Weeks, and R. Zhou, “Dewetting and hydrophobic interaction in physical and biological systems,” Annual Review of Physical Chemistry, vol. 60, pp. 85–103, 2009. View at Publisher · View at Google Scholar · View at Scopus
91. B. Caterina, K. Bernd, and S. Martin, “A Medicinal Chemist’s Guide to Molecular Interactions,” Journal of Medicinal Chemistry, vol. 53, no. 14, pp. 5061–5084, 2010. View at Google Scholar
92. B. Kuhn, M. Hennig, and P. Mattei, “Molecular recognition of ligands in dipeptidyl peptidase IV,” Current Topics in Medicinal Chemistry, vol. 7, no. 6, pp. 609–619, 2007. View at Publisher · View at Google Scholar · View at Scopus
93. J.-U. Peters, S. Weber, S. Kritter et al., “Aminomethylpyrimidines as novel DPP-IV inhibitors: A 105-fold activity increase by optimization of aromatic substituents,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 6, pp. 1491–1493, 2004. View at Publisher · View at Google Scholar · View at Scopus
94. M. Zürcher and F. Diederich, “Structure-based drug design: Exploring the proper filling of apolar pockets at enzyme active sites,” Journal of Organic Chemistry, vol. 73, no. 12, pp. 4345–4361, 2008. View at Publisher · View at Google Scholar · View at Scopus
95. R. Agrawal, P. Jain, and S. N. Dikshit, “Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist,” Mini-Reviews in Medicinal Chemistry, vol. 12, no. 2, pp. 87–97, 2012. View at Publisher · View at Google Scholar · View at Scopus
96. L. S. Higgins and A. M. Depaoli, “Selective peroxisome proliferator-activated receptor γ (PPARγ) modulation as a strategy for safer therapeutic PPARγ activation,” The American Journal of Clinical Nutrition, vol. 91, no. 1, pp. 267S–272S, 2010. View at Publisher · View at Google Scholar · View at Scopus
97. L. S. Doshi, M. K. Brahma, U. A. Bahirat, A. V. Dixit, and K. V. S. Nemmani, “Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents,” Expert Opinion on Investigational Drugs, vol. 19, no. 4, pp. 489–512, 2010. View at Publisher · View at Google Scholar · View at Scopus
98. S. Fujimori, K. Murakami, and M. Tsunoda, “Preparation of substituted benzylthiazolidine-2,4-dione derivatives as ligands of human peroxisome proliferator-activated receptor,” PCT Int Appl WO 01, 14, 350, March, 2001.
99. G. R. Madhavan, R. Chakrabarti, R. K. Vikramadithyan et al., “Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives,” Bioorganic and Medicinal Chemistry, vol. 10, no. 8, pp. 2671–2680, 2002. View at Publisher · View at Google Scholar · View at Scopus
100. M. Pfahl, C. Tachdijan, H. A. Al-Shamma, A. Fanju, D. P. N. Pleynet, and L. W. Spran, “Preparation of benzylidene thiazolidinediones and analoga as antidiabetics,” PCT Int Appl WO, 00, 16, 122, March, 2001.
101. P. Neogi, F. J. Lakner, S. Medicherla et al., “Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents,” Bioorganic and Medicinal Chemistry, vol. 11, no. 18, pp. 4059–4067, 2003. View at Publisher · View at Google Scholar · View at Scopus
102. S. P. Sahoo, C. Santini, J. K. Boueres, J. V. Heck, E. Metzger, and V. K. Lombardo, “Preparation of 5-(halo or alkyl)-5-aryl-2,4-thiazolidinedione and oxazolidinedione derivatives as PPAR agonists,” PCT Int Appl WO, 00, 78, 312, December, 2000.
103. B. B. Lohray, V. Bhushan, A. S. Reddy et al., “Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl- containing thiazolidinediones,” Journal of Medicinal Chemistry, vol. 42, no. 14, pp. 2569–2581, 1999. View at Publisher · View at Google Scholar · View at Scopus
104. B. B. Lohray and V. Bhushan, “Indole-containing thiazolidine-2,4-diones as novel euglycemic and hypolipidemic agents: DRF-2189,” Drugs of the Future, vol. 24, no. 7, pp. 751–757, 1999. View at Publisher · View at Google Scholar · View at Scopus
105. M. Oguchi, K. Wada, H. Honma et al., “Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones,” Journal of Medicinal Chemistry, vol. 43, no. 16, pp. 3052–3066, 2000. View at Publisher · View at Google Scholar · View at Scopus
106. G. R. Madhavan, R. Chakrabarti, S. K. B. Kumar et al., “Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents,” European Journal of Medicinal Chemistry, vol. 36, no. 7-8, pp. 627–637, 2001. View at Publisher · View at Google Scholar · View at Scopus
107. V. B. Lohray, B. B. Lohray, R. B. Paraselli, R. Rajagopalan, and R. Chakrabarti, “Preparation of substituted thiazolidinediones having antidiabetic, hypolipidemic and antihypertensive properties,” US Patent 6, 313, 113, November, 2001.
108. D. Gupta, N. N. Ghosh, and R. Chandra, “Synthesis and pharmacological evaluation of substituted 5-[4-[2-(6,7-dimethyl-1,2,3,4-tetrahydro-2-oxo-4-quinoxalinyl)ethoxy]phenyl] methylene]thiazolidine-2,4-dione derivatives as potent euglycemic and hypolipidemic agents,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 4, pp. 1019–1022, 2005. View at Publisher · View at Google Scholar · View at Scopus
109. R. Jeon and S. Park, “Synthesis and biological activity of benzoxazole containing thiazolidinedione derivatives,” Archives of Pharmacal Research, vol. 27, pp. 1099–1105, 2004. View at Google Scholar
110. S. P. Shriram and V. P. Veerapur, “Benzisoxazle containing thiazolidinediones as peroxisome proliferator activated receptor-γ agonists: design, molecular docking, synthesis and antidiabetic studies,” Scholars Academic Journal of Pharmacy, vol. 3, no. 1, pp. 26–37, 2014. View at Google Scholar
111. G. R. Madhavan, R. Chakrabarti, K. Anantha Reddy et al., “Dual PPAR-α and -γ activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential,” Bioorganic and Medicinal Chemistry, vol. 14, no. 2, pp. 584–591, 2006. View at Publisher · View at Google Scholar · View at Scopus
112. M. Tunçbilek, O. Bozdag-Dündar, G. Ayhan-Kilcigil et al., “Synthesis and hypoglycemic activity of some substituted flavonyl thiazolidinedione derivatives - Fifth communication: Flavonyl benzyl substituted 2,4-thiazolidinediones,” Farmaco, vol. 58, no. 1, pp. 79–83, 2003. View at Publisher · View at Google Scholar · View at Scopus
113. J. A. Sattigeri and M. Salman, “Preparation of phenyl acetylene derivatives as agonists of PPAR receptors,” PCT Int Appl WO 058813, June, 2005.
114. M. Onota and Y. Iwai, “Preparation of benzoic acids and thiazolidinediones for N-benzyldioxothiazolidinyl-benzamides as antidiabetic agents,” Japanese Pat, 354, 664, December, 2001.
115. M. Imran, I. Babar, Deepanajali, and A. K. Suroor, “Recent thiazolidinediones as antidiabetics,” Journal of Scientific and Industrial Research, vol. 66, pp. 99–109, 2007. View at Google Scholar
116. R. P. Shashikant, K. Prajact, P. Ashwini, N. Ana, and B. S. Kittur, “Studies on the synthesis of novel thiazolidinedione derivatives with antidiabetic activity,” Iranian Journal of Pharmaceutical Sciences-Autumn, vol. 5, no. 4, pp. 225–230, 2009. View at Google Scholar
117. A. D. Vaibhav and V. B. Prasad, “SAR and computer aided drug design approaches in the discovery of peroxisome proliferator activated receptor γ activators: a perspective,” Journal of Computational Medicine, pp. 1–38, 2013. View at Google Scholar
118. A. Mller-Schiffmann, H. Sticht, and C. Korth, “Hybrid compounds: From simple combinations to nanomachines,” BioDrugs, vol. 26, no. 1, pp. 21–31, 2012. View at Publisher · View at Google Scholar · View at Scopus
119. A. G. Chittiboyina, M. S. Venkatraman, C. S. Mizuno et al., “Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARγ agonists,” Journal of Medicinal Chemistry, vol. 49, no. 14, pp. 4072–4084, 2006. View at Publisher · View at Google Scholar · View at Scopus
120. S. J. Flora, “Structural, chemical and biological aspects of antioxidants for strategies against metal and metalloid exposure,” Oxidative Medicine and Cellular Longevity, vol. 2, no. 4, pp. 191–206, 2009. View at Publisher · View at Google Scholar · View at Scopus
121. B. R. P. Kumar, M. Soni, S. S. Kumar et al., “Synthesis, glucose uptake activity and structure-activity relationships of some novel glitazones incorporated with glycine, aromatic and alicyclic amine moieties via two carbon acyl linker,” European Journal of Medicinal Chemistry, vol. 46, no. 3, pp. 835–844, 2011. View at Publisher · View at Google Scholar · View at Scopus
122. E. P. Haber, H. M. A. Ximenes, J. Procópio, C. R. O. Carvalho, R. Curi, and A. R. Carpinelli, “Pleiotropic effects of fatty acids on pancreatic β-cells,” Journal of Cellular Physiology, vol. 194, no. 1, pp. 1–12, 2003. View at Publisher · View at Google Scholar · View at Scopus
123. C. P. Briscoe, M. Tadayyon, J. L. Andrews et al., “The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids,” Journal of Biological Chemistry, vol. 278, no. 13, pp. 11303–11311, 2003. View at Publisher · View at Google Scholar · View at Scopus
124. R. J. Lefkowitz, “Historical review: A brief history and personal retrospective of seven-transmembrane receptors,” Trends in Pharmacological Sciences, vol. 25, no. 8, pp. 413–422, 2004. View at Publisher · View at Google Scholar · View at Scopus
125. K. Kotarsky, N. E. Nilsson, E. Flodgren, C. Owman, and B. Olde, “A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs,” Biochemical and Biophysical Research Communications, vol. 301, no. 2, pp. 406–410, 2003. View at Publisher · View at Google Scholar · View at Scopus
126. A. Salehi, E. Flodgren, N. E. Nilsson et al., “Free fatty acid receptor 1 (FFA1R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion,” Cell and Tissue Research, vol. 322, no. 2, pp. 207–215, 2005. View at Publisher · View at Google Scholar · View at Scopus
127. K. M. Darwish, I. Salama, S. Mostafa, M. S. Gomaa, and M. A. Helal, “Design, synthesis, and biological evaluation of novel thiazolidinediones as PPAR3/FFAR1 dual agonists,” European Journal of Medicinal Chemistry, vol. 109, pp. 157–172, 2016. View at Publisher · View at Google Scholar · View at Scopus
128. S. Wang, K. S. Awad, J. M. Elinoff et al., “G protein-coupled receptor 40 (GPR40) and peroxisome proliferator-activated receptor γ (PPARγ): An integrated two-receptor signaling pathway,” Journal of Biological Chemistry, vol. 290, no. 32, pp. 19544–19557, 2015. View at Publisher · View at Google Scholar · View at Scopus